Stock Market Reviews

EW (Edwards Lifesciences Corporation) News

Get the latest news, insights, and market updates on EW (Edwards Lifesciences Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
  Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
  Feb 20, 2026 - $EW
• Top Stock Reports for UnitedHealth, Honeywell & Shopify
  UnitedHealth's earnings beat highlights steady Optum-driven growth, even as rising medical costs and debt pressures keep valuation concerns in focus.
  Feb 19, 2026 - $EW
• Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
  IRVINE, Calif., February 19, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences:
  Feb 19, 2026 - $EW
• Bionic Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts to 2033
  The global Bionic Devices Market is projected to surge to approximately USD 11.90 billion by 2033, from USD 6.22 billion in 2025, at a CAGR of 8.45%. Key growth drivers include technological advancements in wearable robotics, rising demand for non-invasive treatments, and increasing chronic illnesses. AI innovations and healthcare spending further enhance bionic devices' performance. Leading companies in this field, such as Abbott Laboratories, Abiomed, and Edwards Lifesciences, are driving glob
  Feb 18, 2026 - $EW
• Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88%
  Key Insights Significantly high institutional ownership implies Edwards Lifesciences' stock price is sensitive to their...
  Feb 16, 2026 - $EW
• Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices?
  AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned surgical offering. This change highlights how competition in cardiac surgery devices can quickly alter perceptions of AtriCure’s positioning, even as other analysts maintain positive views on its prospects. We’ll now examine how JPMorgan’s concerns about Edwards Lifesciences’ competitive threat could...
  Feb 15, 2026 - $EW
• Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update
  Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]
  Feb 15, 2026 - $EW
• Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
  IRVINE, Calif., February 13, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026.
  Feb 13, 2026 - $EW
• BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
  Boston Scientific tops Q4 estimates, but shares sink on supply woes and EP losses. Can strong growth drivers fuel a 2026 rebound?
  Feb 13, 2026 - $EW
• How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025
  On February 10, 2026, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full‑year 2025 sales of US$6.07 billion, alongside sharply lower net income despite double‑digit revenue growth. The company paired this with 2026 guidance targeting 8%–10% sales growth and earnings per share of US$2.90–US$3.05, underpinned by expanding TAVR and TMTT valve portfolios. We’ll now examine how Edwards’ confident 2026 sales and EPS guidance reshapes the earlier investment narrative around...
  Feb 12, 2026 - $EW